Disease · EFO_1001459

diabetic foot

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. diabetic foot. Diseases, record EFO_1001459. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001459

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: diabetic foot; Open Targets
Open Targets ID: EFO_1001459; Open Targets
Other names: Diabetic Feet, Diabetic Foot Ulcer; Open Targets
MeSH: D017719; MeSH
Highest stage of its drugs: Approval, for 5 of its 82 drugs, from DailyMed and TTD; Open Targets

Drugs82

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ALPROSTADIL	CHEMBL495	Small molecule	Approval	TTD	2	1	1	Drugs and targets
PEXIGANAN	CHEMBL1275802	Protein	Approval	TTD	2	1	1	Drugs and targets
NITROGLYCERIN	CHEMBL730	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PIPERACILLIN SODIUM	CHEMBL1200820	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TAZOBACTAM SODIUM	CHEMBL1439	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
BECAPLERMIN	CHEMBL1201556	Protein	Phase 3	ClinicalTrials.gov and TTD	6	5	4	Drugs and targets
ACLERASTIDE	CHEMBL4297940	Protein	Phase 3	ClinicalTrials.gov and TTD	4	3	3	Drugs and targets
ACT-1 PEPTIDE	CHEMBL4297964	Protein	Phase 3	ClinicalTrials.gov and TTD	4	2	1	Drugs and targets
ESMOLOL HYDROCHLORIDE	CHEMBL1201115	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
BEMIPARIN	CHEMBL3707365	Oligosaccharide	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 82

See all 82 drugs

Targets69

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Phase 2	https://conductscience.org/library/genes/2057	Drugs and targets
GUCY1A1	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2982	Drugs and targets
GUCY1A2	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2977	Drugs and targets
GUCY1B1	Soluble guanylate cyclase	3	Soluble guanylate cyclase activator	Approval	https://conductscience.org/library/genes/2983	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
ADORA2A	Adenosine receptor A2a	1	Adenosine A2a receptor agonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 agonist	Phase 1/2	https://conductscience.org/library/genes/1141	Drugs and targets
COL11A1	Collagen	1	Collagen hydrolytic enzyme	Phase 1	https://conductscience.org/library/genes/1301	Drugs and targets

1 to 10 of 69

See all 69 targets

Trials69

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00662831	Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients	Phase 2/3	276	2012-01-13	Diabetic Foot Ulcer	DALTEPARIN SODIUM	Its record names the disease	ClinicalTrials.gov
NCT01217476	The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study	Phase 3	207	2014-08-05	Diabetic Foot Ulcer of Neuropathic Origin	TRAFERMIN	Its record names the disease	ClinicalTrials.gov
NCT01217463	The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study	Phase 3	201	2014-08-05	Diabetic Foot Ulcer of Neuropathic Origin	TRAFERMIN	Its record names the disease	ClinicalTrials.gov
NCT01594762	Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers	Phase 3	200	2017-06-14	Diabetic Foot Infection	PEXIGANAN	Its record names the disease	ClinicalTrials.gov
NCT03998436	Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers	Phase 3	176	2023-09-22	Diabetic Foot Ulcer	ESMOLOL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00796744	Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers	Phase 2	78	2012-09-27	Foot Ulcer, Diabetic, Diabetic Foot	ACLERASTIDE	Its record names the disease	ClinicalTrials.gov
NCT02789033	Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers	Phase 3	68	2021-01-12	Diabetic Foot Ulcers	ISOSORBIDE DINITRATE, POLIGLUSAM	Its record names the disease	ClinicalTrials.gov
NCT01831804	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863	Phase 1	65	2019-08-19	Wound Healing	DAPRODUSTAT	Its record names the disease	ClinicalTrials.gov
NCT03282981	Beta Adrenergic Antagonist for the Healing of Chronic DFU	Phase 3	48	2025-04-25	Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers, Non Healing Wound	TIMOLOL	Its record names the disease	ClinicalTrials.gov
NCT01113515	Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers	Phase 1/2	44	2024-05-20	Diabetic Foot Ulcer	ESMOLOL HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 69

See all 69 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dalteparin vs Placebo: Number of Participants Who Died	4 of 184	3 of 92	276	NCT00662831	Trial comparisons
Dalteparin vs Placebo: serious adverse events	33 of 184	18 of 92	276	NCT00662831	Trial comparisons
Dalteparin vs Placebo: Number of Participants Who Underwent Any Amputation	8 of 180	2 of 90	270	NCT00662831	Trial comparisons
Trafermin vs Placebo: serious adverse events	20 of 105	26 of 102	207	NCT01217476	Trial comparisons
Trafermin vs Placebo: serious adverse events	23 of 99	17 of 102	201	NCT01217463	Trial comparisons
Topical Pexiganan Cream 0.8% vs Topical Placebo Control: Number of Participants With Clinical Response	56 of 97	54 of 103	200	NCT01594762	Trial comparisons
Topical Pexiganan Cream 0.8% vs Topical Placebo Control: deaths from any cause	0 of 97	0 of 103	200	NCT01594762	Trial comparisons
Topical Pexiganan Cream 0.8% vs Topical Placebo Control: serious adverse events	8 of 97	2 of 103	200	NCT01594762	Trial comparisons
Topical Pexiganan Cream 0.8% vs Topical Placebo Control: Number of Participants With Microbiological Response	18 of 63	27 of 75	138	NCT01594762	Trial comparisons
Timolol vs SOC Plus Non Biologically Active Gel: Percentage of Complete Wound Closure, as Assessed Over a 12 Week Period	8 of 21	7 of 27	48	NCT03282981	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials31

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25410983	RESULT	1	PubMed
24814697	RESULT	1	PubMed
24350844	RESULT	1	PubMed
23992903	RESULT	1	PubMed
23863187	RESULT	1	PubMed
23736928	RESULT	1	PubMed
22672145	RESULT	1	PubMed
22513920	RESULT	1	PubMed
20923537	RESULT	1	PubMed
20873963	RESULT	1	PubMed

1 to 10 of 31

See all 31 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001459

GET https://conductscience.org/api/diseases/v1/EFO_1001459/drugs?page=2

API reference For AI assistants